DUBLIN, Aug. 27,
2024 /PRNewswire/ -- Theravance Biopharma, Inc.
(NASDAQ: TBPH) will participate in a Fireside Chat at the H.C.
Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am
PT/3:00 pm IST) and will be
hosting in-person meetings with the investment community at the
conference.
Webcast of the event may be accessed by visiting Theravance.com,
under the Investors section, Events and Presentations. Replay of
the webcast will be archived on the Company's website for 30
days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines
that Make a Difference® in people's lives. In
pursuit of its purpose, Theravance Biopharma leverages decades of
expertise, which has led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution indicated for
the maintenance treatment of patients with chronic obstructive
pulmonary disease (COPD). Ampreloxetine, its late-stage
investigational once-daily norepinephrine reuptake inhibitor in
development for symptomatic neurogenic orthostatic hypotension
(nOH) in patients with Multiple System Atrophy (MSA), has the
potential to be a first in class therapy effective in treating a
constellation of cardinal symptoms in MSA patients. The Company is
committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the
Cross/Star logo are registered trademarks of the Theravance
Biopharma group of companies (in the U.S. and
certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing in this press release
are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302231359.html
SOURCE Theravance Biopharma, Inc.
